Michael Egholm - 04 Apr 2025 Form 4 Insider Report for STANDARD BIOTOOLS INC. (LAB)

Role
President & CEO, Director
Signature
/s/ Michael Egholm by Hanjoon Alex Kim, Attorney-in-Fact
Issuer symbol
LAB
Transactions as of
04 Apr 2025
Transactions value $
-$61,713
Form type
4
Filing time
08 Apr 2025, 16:04:11 UTC
Previous filing
24 Mar 2025
Next filing
22 May 2025
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction LAB Common Stock Options Exercise $0 +197K +7.45% $0.00 2.83M 04 Apr 2025 Direct
transaction LAB Common Stock Tax liability -$61.7K -57.7K -2.04% $1.07 2.77M 04 Apr 2025 Direct F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction LAB Restricted Stock Units Options Exercise $0 -197K -50% $0.00 197K 04 Apr 2025 Common Stock 197K Direct F2, F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The shares were withheld from the reporting person to satisfy the tax withholding obligations that arose upon the vesting of restricted stock units ("RSUs") granted to the reporting person on April 4, 2022, which grant was originally reported on Form 4 filed with the U.S. Securities and Exchange Commission on April 6, 2022.
F2 Each RSU represents the contingent right to receive one share of the Issuer's common stock.
F3 On April 4, 2022, the Reporting Person was granted 786,049 RSUs, vesting in four equal annual installments beginning on April 4, 2023.